Clinical trials: Toripalimab, completed
Gastric Cancer
Toripalimab Combined With FLOT Neoadjuvant Chemotherapy in Patients With Resectable Gastric Cancer
Gastric cancer is one of the most common malignant tumors of the digestive tract. Gastric cancer patients diagnosed for the first time in China have a higher proportion of advanced stages and a higher postoperative metastasis…
- Trial name
- NCT04354662
- Testing
- Toripalimab, Docetaxel, Fluorouracil
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Advanced Solid Tumors
A Study to Evaluate YH003 in Combination With Toripalimab (Anti-PD-1 mAb) in Subjects With Advanced Solid Tumors
This is a phase I/II, multi-center, open-label study of YH003 in combination with Toripalimab (anti-PD-1 mAb). The study is comprised of a dose escalation part (Part I) exploring escalating doses of YH003 in combination with…
- Trial name
- NCT04481009
- Testing
- YH003, Toripalimab, Nab-paclitaxel
- Where
- Australia
- Volunteers
- 26 people
- Sponsor
- Eucure (Beijing) Biopharma Co., Ltd
Advanced Solid Tumor
Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors
We conducted a single-center, prospective randomized ,Parallel controls, open labels Clinical Studies,The study is about Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients with malignant Advanced…
- Trial name
- NCT05809336
- Testing
- Inosine 0.2g orally 3 times/day, PD-1/PD-L1 inhibitor ,chemotherapy/targeting
- Where
- China
- Volunteers
- 172 people
- Sponsor
- Beijing Friendship Hospital
Hepatocellular Carcinoma, Anti-PD1 Antibody
Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma
For the advanced hepatocellular carcinoma (HCC), the targeted therapy and immunotherapy are recommended. This study focused on the management of Lenvatinib combined anti-PD1 antibody for the HCC.
- Conditions
- Hepatocellular Carcinoma, Anti-PD1 Antibody, Liver Diseases
- Trial name
- NCT04627012
- Testing
- Lenvatinib, Opdivo, Camrelizumab
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Sun Yat-sen University
Hepatocellulcar Carcinoma
Efficacy and Safety Comparison Between PD-1 Inhibitor Combined With Lenvatinib or With Regorafenib For UHCC After Failure of First-line Treatment
There is no definitive evidence regarding the therapeutic efficacy of PD-1 inhibitors combined with tyrosine kinase inhibitors (TKIs) after disease progression following first-line treatment with bevacizumab plus sintilimab for…
- Trial name
- NCT07537985
- Testing
- Lenvatinib, Regorafenib, PD-1 Inhibitor
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Sun Yat-sen University
Metastatic Renal Cell Carcinoma
Pretreatment 18F-FDG PET/CT Radiomics for Predicting Response to First-Line Targeted Therapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma
This single-center retrospective observational study evaluates whether quantitative imaging features from pretreatment 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) can help predict…
- Trial name
- NCT07827482
- Testing
- Pretreatment 18F-FDG PET/CT, Axitinib Plus Pembrolizumab or Toripalimab
- Where
- China
- Volunteers
- 228 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Cholangiocarcinoma, Intrahepatic
Two-cohort Study of Toripalimab(PD1)+Lenvatnib, or Gemox+Lenvatinib in Advanced Intrahepatic Cholangiocarcinoma
We aim to explore the effects and safety of the two cohorts of toripalimab combined with lenvatinib or gemox combined with lenvatinib as first-line therapy in advanced or unresectable intrahepatic cholangiocarcinoma
- Trial name
- NCT04361331
- Testing
- Lenvatinib combined with gemox, Toripalimab combined with lenvatinib
- Where
- 2 sites in China
- Volunteers
- 61 people
- Sponsor
- Shanghai Zhongshan Hospital
Advanced Malignancies
Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies
The primary objective is to assess the safety and tolerability of Toripalimab in subjects with various advanced malignancies and to evaluate the recommended Phase 2 dose.
- Trial name
- NCT03474640
- Testing
- Part A, Part B
- Where
- 14 sites in United States
- Volunteers
- 184 people
- Sponsor
- TopAlliance Biosciences
Hepatocellular Carcinoma
HAIC Plus Lenvatinib and Toripalimab for Advanced HCC
The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin plus lenvatinib and toripalimab in patients with advanced hepatocellular…
- Trial name
- NCT04044313
- Testing
- Hepatic arterial infusion chemotherapy, Lenvatinib, Toripalimab
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Shi Ming
Non-Small-Cell Lung Cancer Stage IV
Clinical Trial Assessing the Efficacy of Abscopal Effect Induced by SBRT and Immunotherapy in Advanced NSCLC
This is a prospective, multicenter, open-label study to observe the effect of SBRT and immunotherapy combined with Bevacizumab or not in stage IV non-squamous non-small cell lung cancer (NSCLC) with previously failed after…
- Trial name
- NCT04238169
- Testing
- Bevacizumab, Toripalimab, SBRT
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Xinqiao Hospital of Chongqing
NSCLC
The Pharmacokinetics and Safety of Single-dose and Parallel Comparisons in Patients With NSCLC Treated With JS001
This study was designed to evaluate the similarity of single-dose and parallel comparisons of recombinant humanized anti-PD-1 monoclonal antibody injections before and after process changes.
- Trial name
- NCT03301688
- Testing
- Toripalimab
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Malignant Lymphoma
Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Toripalimab for Patients With Recurrent Malignant Lymphoma
The primary objective is to assess the safety and tolerability of JS-001 in subjects with recurrent malignant lymphoma, and to evaluate its preliminary efficacy.
- Trial name
- NCT03316144
- Testing
- Toripalimab
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Advanced Solid Tumor
A Study to Assess YH001 in Combination With Toripalimab Injection in Subjects With Advanced Solid Tumors
This is an open-label, dose-escalation study of YH001 administered intravenously (IV) in combination with Toripalimab. The study is designed to determine the safety, tolerability and maximum tolerated dose (MTD) or recommended…
- Trial name
- NCT04357756
- Testing
- YH001, Toripalimab
- Where
- 3 sites in Australia
- Volunteers
- 29 people
- Sponsor
- Eucure (Beijing) Biopharma Co., Ltd
Hepatocellular Carcinoma
TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC
The purpose of this study is to evaluate the safety and efficacy of transarterial chemoembolization (TACE) in combination with PD-1/PD-L1 Inhibitors and molecular target therapies in patients with Intermediate-stage…
- Trial name
- CHANCE2202 (NCT05332496)
- Testing
- PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE
- Where
- 2 sites in China
- Volunteers
- 941 people
- Sponsor
- Zhongda Hospital
NSCLC
Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC
The purpose of this study is to explore the efficacy and safety of toripalimab combined with anlotinib and SBRT for non-driver gene mutation untreated brain metastases non-small Cell Lung Cancer.
- Trial name
- NCT05021328
- Testing
- Toripalimab, Anlotinib, SBRT 7Gy✖️5 QD
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Hubei Cancer Hospital
Metastatic Colorectal Adenocarcinoma
Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRC
Fruquintinib with PD-1 inhibitors (FP) and TAS-102 with bevacizumab (TB) are two common therapies for patients with previous-treated metastatic colorectal cancer (mCRC).
- Trial name
- NCT06031376
- Testing
- Fruquintinib, PD-1 inhibitors, Trifluridine/Tipiracil
- Where
- China
- Volunteers
- 106 people
- Sponsor
- Hunan Cancer Hospital
Advanced Solid Tumor
A Phase I/II Study of TJ004309 for Advanced Solid Tumor
This study is a phase I/II study of single drug TJ004309 and Toripalimab combine treatment for Advanced solid tumor. This study include two stages. First stage is dose escalation and second stage is dose extension.
- Trial name
- NCT04322006
- Testing
- TJ004309, Toripalimab
- Where
- 23 sites in China
- Volunteers
- 225 people
- Sponsor
- TJ Biopharma Co., Ltd.
Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma
Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
This is a Phase 1/1b, open-label, first-in-human, dose-escalation and expansion study of CHS-388, a monoclonal antibody that targets IL-27, as a monotherapy and in combination in patients with solid tumors.
- Conditions
- Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT04374877
- Testing
- CHS-388, Pembrolizumab, Toripalimab
- Where
- 23 sites in United States, Singapore and 1 more
- Volunteers
- 145 people
- Sponsor
- Coherus Oncology, Inc.
Neoadjuvant Therapy of Non-metastatic Locally Advanced Renal Cell Carcinoma
Toripalimab Combined With Axitinib as Neoadjuvant Therapy in Patients With Non-metastatic Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma
This study is design to prospectively investigate the safety and efficacy of Toripalimab combined with Axitinib in downsizing tumors in patients with nonmetastatic biopsy-proven clear cell renal cell carcinoma.
- Trial name
- NCT04118855
- Testing
- Toripalimab, Axitinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- RenJi Hospital
Melanoma, Renal Carcinoma
A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JS004 in Advanced Solid Tumors
An open-label, dose-escalation, phase I clinical study to evaluate the safety and tolerability of JS004 injection in the patients with advanced solid tumors who have failure in standard of care and are unable to tolerate standard…
- Conditions
- Melanoma, Renal Carcinoma, Urothelial Carcinoma
- Trial name
- NCT04773951
- Testing
- JS004, a recombinant humanized, IgG4κ monoclonal antibody (mAb) specific to B- and T-lymphocyte attenuator (BTLA); Toripalimab Injection
- Where
- 11 sites in China
- Volunteers
- 47 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.